Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline

Evaluation of Two Methods for the Echocardiographic Assessment of Intrapulmonary Vasodilatation in Patients With Liver Cirrhosis: Agitated Saline Versus Polygelatine

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00343122

Enrollment

100

Registered

2006-06-22

Start date

2006-06-30

Completion date

Unknown

Last updated

2007-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver

Keywords

liver, cirrhosis, hepatopulmonary syndrome

Brief summary

The purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.

Detailed description

Intrapulmonary vasodilatation is a frequent finding in patients with cirrhosis. Its diagnosis is established via contrast enhanced echocardiography. One used method is the contrast agent agitated saline and another frequently used method is the contrast agent polygeline. The purpose of this study is to compare these two echocardiographic contrast agents with respect to their ability to detect intrapulmonary vasodilatation.

Interventions

PROCEDUREechocardiography for intrapulmonary vasodilatation

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age \> 18 years * presence of liver cirrhosis * evaluation for liver transplantation or transjugular intrahepatic portosystemic shunt

Exclusion criteria

* inadequate echocardiographic image quality * allergies to echocardiographic contrast agents * pulmonary valve stenosis * pulmonary embolism * relevant tricuspid regurgitation * cardiomyopathy

Countries

Austria

Contacts

Primary ContactValentin Fuhrmann, MD

valentin.fuhrmann@meduniwien.ac.at0043-1-40400

Backup ContactPeter Schenk, MD

0043-1-40400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026